Health funding

Clinics On Cloud provides cloud-based solutions for healthcare providers, enabling them to manage their operations more efficiently. The company targets clinics and healthcare facilities looking to modernize their services. This funding round will help expand their technology offerings and reach more clients in the healthcare sector.

Zafrens is a San Diego-based drug discovery company that has developed the Z-Screen platform, combining microfluidics, longitudinal cell imaging, and sequencing to rapidly test large numbers of potential medicines. The company aims to validate biological hypotheses faster than traditional methods by linking molecular data to cell function at high throughput. This funding will advance its internal drug pipeline and expand its screening platform.

Aioss is a Danish wellness startup that has raised $1.12M in seed funding. The round was backed by notable individuals Kesi and Medina. The company operates in the wellness sector.

Activ Surgical is a Boston-based digital surgery company developing tools that give surgeons enhanced visualization capabilities, allowing them to see otherwise invisible structures like blood flow in real-time. This Series B funding will support the commercialization of their ActivSight hardware, European market expansion, and the development of AI-based projects to further augment surgical insights.

Brise Pharma, a Beijing-based company, has entered into a discovery and commercialization deal with AbbVie for two preclinical migraine programs. This partnership aims to advance the development of novel treatments for migraine.

Confido Health is an India-built startup developing AI agents to automate administrative tasks for clinics, such as appointment booking, insurance eligibility checks, and care coordination. The company aims to fix inefficiencies in the healthcare system, initially focusing on the US market. This Series A funding will support scaling sales, growing engineering teams in India and Brazil, and enhancing their AI capabilities.

Vera Health has raised $29 million for its clinician search tool. The platform has surpassed 800,000 users, indicating significant adoption and demand for its services in the healthcare sector.

Brandon University researcher Dr. Mousumi Majumder has received a five-year, $500,000 renewal of her Canada Research Chair to investigate breast cancer treatment resistance. The funding will support research into triple-negative breast cancer and the development of new ways to predict patient outcomes, aiming to help doctors stay ahead of treatment resistance.

Jagruti Rehabilitation Centre is a Pune-based chain of residential centers offering care for mental health, addiction, and dementia. Founded in 2008, it has grown to over 19 centers across nine cities, providing structured, compassionate, and clinically guided care. The company plans to expand significantly with its recent Series A funding.

Docterz is a Mumbai-based healthtech startup that provides clinic management software for doctors. The company aims to use its recent funding to grow organically, explore acquisitions, and develop AI tools for healthcare professionals. It focuses on serving independent practitioners, smaller clinics, and healthcare organizations across India.

Blue Arbor Technologies is developing the RESTORE Neuromuscular Interface System, designed for independent and simultaneous control of prosthetic limbs. The company is advancing both external and implantable versions of its sensing interface. This funding will support feasibility studies and regulatory efforts for clinical trials.

StimCardio is a clinical-stage medical device company developing non-invasive wearable therapeutics for atrial fibrillation (AF). Their lead product, Rhyvive, is designed to extend AF treatment beyond the hospital and into the home, targeting a significant unmet clinical need in cardiac electrophysiology.

NeuroXess is a Chinese startup developing implantable brain-computer interface systems. Their technology combines flexible electrodes with wireless power and data transmission for movement and speech decoding, as well as external device control. This Series B funding will support clinical trials, regulatory submissions, manufacturing expansion, and next-generation product development.

Atlas Bio is a Swiss startup focused on improving drug development by tackling the high failure rate and aiming to move beyond animal testing. This funding round will support their efforts to create more effective and ethical pharmaceutical research processes.

adsilico is a University of Leeds spinout that utilizes AI and simulation technology to assess medical device performance in virtual patient populations. The company aims to improve the representation of diverse patient demographics in clinical trials, thereby enhancing the safety and efficacy of medical devices.

Imphatec is a British synthetic biology pharmaceutical company developing a customizable-dose subcutaneous implant platform for patients with chronic and long-term conditions. The company aims to create a 'pill-free future' by providing implants that release personalized doses over the long term without patient input.

CureBay is a rural healthtech startup that provides primary healthcare services to small towns and villages in India. It operates a network of tech-enabled clinics offering consultations, diagnostics, and preventive care, aiming to make quality healthcare accessible to underserved communities.

Vitalls is a UAE-based startup developing an AI-powered digital health passport that allows individuals to store, manage, and share their health records securely. The platform aims to address the fragmentation of medical records across different healthcare systems, providing users with control over their medical histories.

Genie Health is a Singapore-based startup that transforms fragmented health information into actionable intelligence for individuals and healthcare providers. Their platform aims to help individuals understand their health and empower providers to deliver more personalized care. This seed funding will accelerate the adoption of their personal health app and clinic intelligence solution, deepening platform capabilities and growing their team.

Cellbox is a company focused on the transport of biological material. They have successfully raised a €5 million Series A funding round to advance their services in this specialized logistics sector.

Emerald is a preventive health platform that provides blood screening in clinics and an app that combines test results, wearable data, and individual health history. The company aims to reach one million members in the next three years, having already increased its membership tenfold and conducted over 100,000 laboratory tests.

XRlabs is a London-based company focused on integrating artificial intelligence into surgical procedures. The funding will help enhance their technology aimed at improving surgical outcomes and efficiency in operating rooms.

Nouscom is a biotechnology company developing novel cancer immunotherapies. Their innovative approach aims to bring advanced treatments closer to clinical trials. This funding will support the advancement of their pipeline.

OMass Therapeutics, an Oxford-based company, has raised $310 million in a Series C financing round. The funds will be used to advance its small-molecule pipeline for rare endocrine and immunology disorders, including a potential treatment for congenital adrenal hyperplasia. This financing is the second-largest private biotech round in Europe for 2026.

Matria is a Brazilian healthtech company that builds AI agents on its Healthcare Data Fabric to connect fragmented hospital data across Latin America. The platform automates exam scheduling, payment organization, and clinical item checks by turning unstructured data into patient context. This seed round will fund expansion in Brazil and Mexico.

Soufflé Therapeutics is developing cell-specific RNA delivery platforms to treat genetic diseases. Their REMEDY platform aims to deliver oligonucleotide therapies to specific cells outside the liver, addressing a key bottleneck in genetic medicine. This Series B funding will advance their lead programs targeting facioscapulohumeral muscular dystrophy (FSHD) and heart failure into clinical studies.

A company focused on combating a muscle disease has raised $37 million. This funding is part of a broader initiative by a billionaire to address the condition.

Microbiotica is developing a new treatment for inflammatory bowel disease. The company has secured €42 million in funding to advance its novel therapies. This funding will support the progression of their pipeline and further research into gut microbiome-based treatments.

Sunfox is a cardiac diagnostics startup that has raised $7 million in funding. The company focuses on developing innovative solutions for heart health monitoring and diagnosis.

B-Arm is a women's healthcare brand that has raised Rs 4.8 crore in funding. The company aims to provide comprehensive healthcare solutions for women, stemming from a mother's personal journey. This funding will likely support the expansion of their services and product offerings.

SpectaCell is a Ghent-based startup specializing in next-generation cell therapy analytics. They have launched with €6 million in Seed funding to advance their platform, which combines digital imaging and data analysis to measure how treatments affect individual cells. The company aims to provide researchers with detailed insights faster, improving the development of immunotherapies.

Sava is developing a sensor technology aimed at replacing fingerstick glucose testing. The company has secured $36 million in Series B funding, led by Ascensia, to support the commercialization and distribution of its products in Europe. Their goal is to obtain CE approval for insulin dosing without fingerstick checks within 18-24 months.

Sava Technologies is a London-based HealthTech company developing a wearable biosensor platform that detects molecules beneath the skin. They have raised €32.08 million in a Series B round to fund manufacturing scale-up and commercial readiness. The company has also partnered with Ascensia for commercialization and distribution in Europe.

Phantom GI is developing a novel device, PercStoma, designed to create an ostomy using a needle puncture and local anesthesia, bypassing the need for invasive abdominal surgery. This technology targets patients with bowel obstruction who are considered inoperable with conventional methods, potentially reducing risks and costs associated with traditional surgical procedures.

Yazen is a Swedish health startup offering a weight-loss program centered around popular weight-loss drugs. The company is experiencing steady growth and has secured funding to support its operations for the next few years. This round highlights investor interest in companies capitalizing on the trend of weight-loss drugs.

A startup founded by a Nobel Prize winner has raised $350 million. However, the company is now facing funding challenges for its cancer programs. The article does not provide further details on the company's specific focus or the implications of the funding shortfall.

Vitalize is a company focused on addressing hospital staffing shortages. The company has raised $31 million to tackle this critical issue within the healthcare sector.

Absci is a drug discovery company that uses AI to develop new medicines. They are focused on automating the drug manufacturing process. This funding round will help them advance their AI-powered drug discovery platform.

WhiteLab Genomics is developing AI-powered solutions for medicine design. The company aims to accelerate the discovery and development of new therapies. This funding will support their ongoing research and development efforts.

Primerry is a paediatric healthcare brand developing everyday health products for children aged two to 14 years. The company aims to provide trustworthy, clean formulations with unique delivery formats that children will enjoy. They plan to use their recent pre-seed funding to expand their product range and distribution network across India.

XLerateHealth is a commercialization platform that helps universities, biotech hubs, health systems, and other organizations bring early-stage healthcare and life sciences discoveries to market. They plan to use the NIH grant to expand their software architecture, curriculum, AI tools, and expert marketplace. The platform is designed for institutional partners to manage commercialization programs or license their software.

Breye Therapeutics is developing oral therapies for the early treatment of retinal diseases. This funding will advance their pipeline of novel treatments. The company aims to provide more accessible and convenient options for patients suffering from conditions like age-related macular degeneration and diabetic retinopathy.

Omnio is developing a plasminogen-based therapy for chronic wounds. This funding will advance their therapy for hard-to-heal wounds. The company is based in Sweden.

Aptadir Therapeutics is developing a new class of RNA inhibitor-based therapeutics called DNMTs Interacting RNAs (DiRs) to address genetic disorders and oncology. Their platform aims to reactivate silenced genes and restore normal biological functions, potentially offering a way to treat previously irreversible genetic diseases. This seed round will advance their lead candidate for Fragile X Syndrome towards clinical development.

Carebot is a Czech startup developing AI-powered medical scans. The company has raised a record 36 million Czech crowns to further develop its technology and expand its reach.

Vytalyou is a longevity healthcare startup that has raised ₹9 Crore in a Pre-Series A round. The company plans to use the funds to open two new clinics in Mumbai.

Aignosis is a healthtech startup that has developed AI-assisted autism and developmental screening technology. The company aims to make autism screening more accessible across India's healthcare ecosystem, working with both public and private settings. This seed funding will be used to scale their technology and expand its reach.

Lumin is a Wauwatosa-based biotech startup developing a blood test to commercialize its technology. The company has raised $1.5 million to advance its product development and market entry.

Ai3Bio has launched with a $48 million Series A funding round. The company aims to reset the immune system, suggesting a focus on novel therapeutic approaches for immune-related diseases.